Resources Repository
-
DataWeb Portal 2024Healthcare Cost and Utilization Project (HCUP)
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in …
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in the United States, including information on in-patient care, ambulatory care, and emergency department visits. HCUP enables researchers, insurers, policymakers and others to study health care delivery and patient outcomes over time, and at the national, regional, State, and community levels. The Agency for Healthcare Research and Quality (AHRQ) provides a range of data resources in the form of online, searchable…
Test Performance | Costing Methods | Health Outcomes | Health/Medicine | North America | Policy/Regulation | Infectious Diseases | Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Economics/Finance | Government/Law | Science/Technology -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Test Performance | Costing Methods | Health Outcomes | Health/Medicine | North America | Policy/Regulation | Infectious Diseases | Decision Analysis | Cost-Effectiveness Analysis | Technology Assessment | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Economics/Finance | Government/Law | Science/Technology -
ArticlePublication 2021Racial and Ethnic Inequities in the Early Distribution of U.S. COVID-19 Testing Sites and Mortality
In 2020, U.S. COVID-19 testing sites were pivotal not just for diagnosis but also to …
In 2020, U.S. COVID-19 testing sites were pivotal not just for diagnosis but also to provide data that would contribute to understanding transmission. This research explored how these sites were distributed in relation to racial and ethnic demographics and its connection to observed disparities in COVID-19 outcomes. Data from mid-April to late May 2020 revealed that testing sites were not equally distributed among racial groups. Specifically, there was an overrepresentation of testing sites in areas…
Test Performance | Health Outcomes | Health/Medicine | North America | Policy/Regulation | Infectious Diseases | Social Determinants | Culture/Society | Science/Technology -
BookPublication 1980Clinical Decision Analysis
This text was conceived and developed in the Harvard T.H. Chan School of Public Health …
This text was conceived and developed in the Harvard T.H. Chan School of Public Health at the Center for the Analysis of Health Practices. The book had its origins in a set of classroom materials developed during the academic year 1974-75 for an elective course in medical decision making at the Harvard Medical School. In this book students are shown how to structure clinical decision problems, how to systematically formulate the intertwining roles of diagnosis and treatment, how to…
Test Performance | Costing Methods | Health Outcomes | Value of Information | Health/Medicine | North America | Infectious Diseases | Probability/Bayes | Preferences/Values | State-Transition | Decision Analysis | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Economics/Finance | Global | Europe | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Costing Methods | Health Outcomes | Value of Information | Health/Medicine | North America | Policy/Regulation | Preferences/Values | Priority Setting/Ethics | Evidence Synthesis | Cost-Effectiveness Analysis | Health Systems | Economics/Finance -
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
Benefit-Cost Analysis | Health/Medicine | North America | Policy/Regulation | Infectious Diseases | Mathematical Models | State-Transition | Business/Industry | Economics/Finance | Government/Law -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Benefit-Cost Analysis | Health/Medicine | North America | Policy/Regulation | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Economics/Finance | Global -
ArticlePublication 2021Individual and Social Determinants of COVID-19 Vaccine Uptake
This article examined the individual, communication and social determinants associated with COVID-19 vaccine uptake using …
This article examined the individual, communication and social determinants associated with COVID-19 vaccine uptake using national survey data collected before vaccines were available in the U.S. Of note, individuals under the federal poverty level and racial and ethnic minorities were oversampled. Outcomes included the likelihood of vaccinating self and dependents (e.g., children). Independent variables included perceptions of risk, exposure to different media for COVID-19 news, political party identification, confidence in scientists and social determinants of…
Health Outcomes | Health/Medicine | North America | Policy/Regulation | Infectious Diseases | Evidence Synthesis | Social Determinants | Clinical Care | Culture/Society | Science/Technology -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Test Performance | Health/Medicine | North America | Policy/Regulation | Infectious Diseases | Probability/Bayes | Technology Assessment | Health Systems | Government/Law | Global